chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report received from a health care professional concerned a 71 year old female of unspecified ethnic origin. The patient's height, and weight were not reported. The patient's concurrent conditions included: immunocompromised. The patient previously received Covid-19 vaccine ad26.cov2.s (dose number in series 1) suspension for injection, route of admin, and batch number and expiry date were not reported) 1 total, dose was not reported, start therapy date were not reported for prophylactic vaccination. On an unspecified date, the patient was down for six hours with exhaustion after receiving Janssen Covid-19 vaccine with first dose of Covid-19 vaccine ad26. cov2.s (dose number in series 1). On an unspecified date, patient was recovered from down for six hours with exhaustion. The patient additionally received Covid-19 vaccine ad26.cov2.s  (dose number in series 2) (suspension for injection, route of admin, and batch number and expiry date were not reported) 1 total, dose was not reported, administered on NOV-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On an unspecified date, the patient was down for six hours with exhaustion after receiving Janssen Covid-19 booster vaccine (dose number in series 2). The action taken with Covid-19 vaccine ad26.cov2.s was not applicable. On an unspecified date, patient was recovered from down for six hours with exhaustion. This report was non-serious. This case, involving the same patient is linked to 20220410217.
Client reports that on 3/19/2021, around 0900 received J & J COVID 19 vaccine at facility. On the day of receiving vaccine no concerns with symptoms and on 3/29/2021, day ten after receiving vaccine starting having pain in right shoulder and right arm injection site, on going. Client stated that two days ago slept on left side and now having numbness/tingling in right hand, no SOB, dizziness, coughing or alter mental status. Client does recall having maybe six times, since the vaccine, head pressure "like a sinus headache". Per Client, already reached out to PCP and was told to follow up if symptoms persisted. PHN recommended that Client follow-up today with PCP to be seen or go into Urgent Care, ER and to always call 911 with medical emergency. Client expressed understanding information provided by PHN during TC. Per Client plan to call and follow up with PCP today.
Pt is a 63 y.o. male with PMH of seizure disorder, recently + for covid-19, GERD who presented to the hospital for query seizure like episode and hypoxia   The patient appeared to be lethargic on interview but was able to provide sufficient history. He noted that he was tested positive for covid-19 10 days ago and his symptoms were mostly fatigue. He has not felt shortness of breath but does endorse some pleurisy pain on inspiration. No subjective fever but he said "someone said I had a fever today". He was recently out of quarantine and sent back to shelter today where he stated that he felt he is having a seizure as he had some eccentric taste in his mouth. No tonic-clonic activity noticed and he has been off his AEDs for about 10 days. He was brought to the ED for evaluation. He was found to be hypoxic around 88% on initial evaluation but was noted saturating in the mid to high 90s on my evaluation on RA.   Respiratory: Positive for cough. Negative for shortness of breath.    On Discharge:  63 y.o. male with history of focal epilepsy, non-small cell lung adenocarcinoma, GERD, COPD and coronary artery disease who presented to the emergency department on 8/28 with concern for pre-seizure aura. His auras are normally a strange taste in his mouth. Patient had recently been without his antiepileptic medications during a 10 day quarantine at a hotel provided by the health department. Patient is currently staying at the a local home shelter.     On arrival patient was reportedly hypoxic, however patient was quickly weaned off of his supplemental oxygen by time of admission. During his short stay he had no seizure-like episodes. His neurological examination is non-focal. He was restarted on his home anti-epileptic medications as well as flonase and a short course of afrin for sinus congestion (chronic, likely worsened by recent COVID infection). Patient has several chronic medical issues, as below, that require close follow-up. Patient does not have a primary care provider. He will follow-up with me in clinic on Wednesday. Patient was provided a bus pass to get to this appointment.   Pt discharged to where he resides at the (home shelter)
Administered expired vaccine of 3 days (expired 5/8/22, given 5/11/22). Dept of health advised to repeat dose due to expiration.
Narrative:  COVID infection following COVID vaccine series 02/19, Pfizer, dose #1 03/12, Pfizer, dose #2 09/01 pt cc: cough, diarrhea, fever, rhinorrhea, exposure: unknown 09/01 COVID swab, result: detected 09/01 SARS-COV-2 Variant Sequencing result: pending 09/14 pt deceased
Information has been received from a health professional concerning a female who was vaccinated on an unspecified on an unspecified date with a dose of GARDASIL vaccine (yeast) (lot# not reported). Subsequently on an unspecified date the patient experienced pain at the injection site and swelling of the arm. The patient's outcome was not reported. This is one of several reports from the same source. Additional information has been requested.
1 day after shot, pt experienced a red rash on injection arm that was warm to the touch and covered the majority of her bicep. She also experienced chills, fever and blisters forming on her lips. After 3 days the symptoms where still present but not getting worse. Acetaminophen helped with her fever and pain.
Within five minutes after receiving the vaccine, I felt a kick and tightness across my chest. I waited at the pharmacy until I felt safe to leave and go home. I got home and felt woozy and lightheaded. On November 29, I was in the kitchen doing housework and I had chest pain and not feeling well at all. I sat down and felt worse. I called my brother, and he took me to the hospital. I had several tests that was all clear except for EKG and my blood pressure was low. They monitored me and my blood pressure. I was discharged on December 8; I had an appointment with my primary care doctor and was referred to a cardiologist. I saw a cardiologist and I had several tests done and showed no heart damage. I had a slight leak in my tricuspid valve but no noticeable murmur.
Site: Pain at Injection Site-Medium, Systemic: Body Aches Generalized-Medium, Systemic: Chest Tightness / Heaviness / Pain-Medium, Systemic: Dizziness / Lightheadness-Medium, Systemic: Exhaustion / Lethargy-Medium, Systemic: Flushed / Sweating-Mild, Systemic: Headache-Medium, Systemic: Hypertension-Medium, Systemic: Joint Pain-Medium, Systemic: Lymph Node Swelling-Medium, Systemic: Nausea-Medium, Systemic: Shakiness-Medium, Systemic: Tachycardia-Severe, Systemic: Tingling (specify: facial area, extemities)-Mild, Systemic: Tinnitus-Mild, Systemic: Unable to Sleep-Mild
Patient came back to the pharmacy 2 days after injection stating she still had soreness in the arm that received the shot. However that pain has persisted. She is still experiencing muscle pain and also limited mobility for which her doctor referred her to physical therapy
Developed pain and redness at injection site 1 day after injection. Also with decreased mobility of arm until 7/20. Redness all the way down her upper (L) arm. No blistering, pustules or fever. Treated with antibiotics to cover possibility of cellulitis. Questionable esponse to antibiotics, so may actually have a hypersensitivity reaction to a component of TRUMENBA.
Patient is fully vaccinated.  COVID + 1/5/2022 on admission to the hospital.  Patient admitted with altered mentation after seizure. Tested positive for covid test.ESRD on HD. Anemia of Chronic disease.Presented to the emergency department secondary to partial altered mental status/partial responsiveness, this was likely secondary to postictal state. CT of the head was completed, which was negative for any acute process and there were negative EKG changes.  Doing well without any signs or symptoms or respiratory compromise, evaluated and cleared by Pulmonary. Discharged home in stable condition.
This spontaneous report as received from a physician refers to an over 50 years old female patient (who was also the doctor's office manager). The patient was vaccinated with ZOSTAVAX (lot # unspecified) subcutaneously on an unknown date. No other co-suspects were reported. No concomitant medications were reported. On an unknown date the patient had a herpes simplex like reaction on her upper lip, and 2 zoster blisters on her waist. She was prescribed an unspecified antiviral. The outcome of the events was reported as recovered. The patient had sought medical attention. Additional information has been requested.
No adverse effect; patient recieved improperly stored VARIVAX; This spontaneous report was received from a nurse practitioner referring to a male patient of unknown age. The patient's medical history, concurrent conditions, drug allergies/reactions and concomitant medications were not reported.   On 23-SEP-2019, the patient was vaccinated with an improperly stored varicella virus vaccine live (Oka/Merck) (VARIVAX) lot #S012039, expiration date: 17-APR-2021(strength, dose, schedule and route of administration were unknown) for prophylaxis (product storage error). The varicella virus vaccine live (Oka/Merck) (VARIVAX) was reconstituted with properly stored sterile diluent (lot # S015238, expiry date 08-MAR-2022. No adverse effect reported.  The vaccine underwent temperature excursion below -9 degree Celsius to 8 degree Celsius (0.84 C) for a duration of 8 hours. There was no previous temperature excursion. There was an involvement of data logger. No product quality complaints (PQC) were involved.
MS FLARED; SUSPECTED COVID-19 INFECTION; REVACCINATION WITH DIFFERENT COVID-19 VACCINE; This spontaneous report received from a patient via other manufacturer (Pfizer) concerned a male of unspecified age, race and ethnicity. The patient's height, and weight were not reported. The patient's concurrent conditions included: multiple sclerosis (MS), and other pre-existing medical conditions included: patient stated he is a sleeping giant. The patient received covid-19 vaccine ad26.cov2.s (Dose number in series 1) (suspension for injection, route of admin, batch number and expiry date were not reported) dose, start therapy date were not reported, 1 total administered for covid-19 prophylaxis. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers.  On an unspecified date, the patient experienced covid-19 (suspected covid-19 infection) (Dose number in series 1).  The patient also received booster dose of non-company suspect vaccine- Pfizer Biontech covid-19 Vaccine (tozinameran) (Dose number in series 2) (suspension, intramuscular, batch number: FE3592, expiry: UNKNOWN) dose was not reported (strength: 2 milliliters, multiple dose vial x 1) administered on 30-NOV-2021 for covid-19 prophylaxis which was associated with revaccination with different covid-19 vaccine (Dose number in series 2). No concomitant medications were reported.  On an unspecified date, after booster dose, the patient experienced MS flared and he had been suffering since (Dose number in series 2). Patient stated that, this did not occur after he had the J and J vaccine and also he did not know if his MS flared due to the vaccine or having covid-19. The action taken with covid-19 vaccine ad26.cov2.s, and tozinameran was not applicable. The patient had not recovered from MS flared, and the outcome of revaccination with different covid-19 vaccine and suspected covid-19 infection was not reported. This report was serious (Other Medically Important Condition). Sender's Comments: V0: 20230352094-MS flared. The event has an unknown/unclear temporal relationship, is unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the event. Specifically: MEDICAL HISTORY. Therefore, this event is considered inconsistent with vaccine administration.
tested positive on at home COVID-19 antigen test on 4/28/22, was being tested at his facility due to a COVID-19 outbreak
Hives, began 1 day after vaccine administ lasting 2 weeks, seen in ER, given prednisone, BENADRYL.
pt is a child w/perinatal depression secondary to a stressful delivery;some concerns regarding hearing & vision;has had a hearing eval & did not pass;given vax & the following day had a fever & sz;briefly hosp & did well;
Patient woke up the next day, after sleeping late. He complained he didn't feel well.  He went to a storage unit with his older sister to help load boxes into her car. They had to stop and rush home. He vomited liquids until clear several times. Then he dry heaved.  Afterwards, he took 2 Ibuprofin, a total dose of 400mg. He went to bed the rest of the day.
My eyes have been blood shot the last 5 days with dilated pupils and pressure behind my eyes. It is starting to fade but the pressure is still there and my eyes are more of a pink now.  I did not go into the Clinic but I did message my Doctor.
Mild GBS symptoms after seasonal flu administration.  10/23/09 Medical Records and Discharge Summary received for DOS 10/12-10/16.  FINAL DX: Polyneuritis acute infectious, chronic obstructive pulmonary disease. New onset lower back pain 2 days s/p flu vaccine. Sx progressed to tingling of toes and soles of feet bil. Presented in ER when pain in calves, triceps, weakness, and diff walking began. Head CT normal. LP abnormal. Areflexia all LE. Mild GBS. IVIG tx x3days. Well tolerated. Upon d/c still w/tingling in hands and feet. Improved strength on ambulation. Neuro follow-up planned.
This case was reported by a pharmacist via call center representative and described the occurrence of rash in a 66-year-old male patient who received SHINGRIX (batch number DD43M, expiry date 7th March 2021) for prophylaxis. On 7th November 2018, the patient received the 1st dose of SHINGRIX (intramuscular). On an unknown date, less than a year after receiving SHINGRIX, the patient experienced rash, lump feeling in throat and swallowing difficult. On an unknown date, the outcome of the rash, lump feeling in throat and swallowing difficult were recovered/resolved. It was unknown if the reporter considered the rash, lump feeling in throat and swallowing difficult to be related to SHINGRIX. Additional details were provided as follows: The patient had no reported allergies. The patient received SHINGRIX vaccine in the left deltoid. The patient experienced a neck rash, lump feeling in throat and difficulty swallowing after receiving SHINGRIX and did not seek medical treatment.
Had contracted chicken pox play-mate days ago. No fever. 50 lesions, stomach, back, legs.
PATIENT WAS GIVEN A PEDIARIX VACCINE INSTEAD OF A BOOSTRIX.  THE PATIENT HAD NO ADVERSE REACTION AND NO SYMPTOMS.
Information has been received from a physician concerning an approximated 75 year old female with no known drugs allergies and medical history, who on 02-MAR-2009 was vaccinated with a dose of ZOSTAVAX (Merck).  On 06-MAR-2009 the patient developed vesicular lesions of the right L3 dermatome distribution.  No laboratories studies performed.  The patient was examined in the office and started on VALTREX.  The patient was recovering.  Follow up information received on 26-MAR-2009 from a herpes zoster questionnaire completed by the physician, stated that the patient had a previous exposure to chickenpox when she was a child, also, the patient had an allergy to COMPAZINE.  It was also reported that the patient was 75 years old.  On 24-FEB-2009 (previously reported as 02-MAR-2009) the patient received a 0.65 mL dose of ZOSTAVAX (Merck) (lot # "01354") into the left upper arm.  Concomitant therapy included PLAVIX, MSD, LIPITOR and TOPROL.  On 26-FEB-2009 the patient developed shingles rash in the right dermatome.  Approximately one hundred lesions were identified to the patient.  The rash did not occur at the site of the injection within the 42 days after vaccination, Fever, chills and flu like syndrome were also reported.  The patient was not recently exposure to Chickenpox.  The patient had a temperature of 100 degrees C and in a scale of 1 to 10 the pain was quantify as 10.  The patient recovered.  The patient was enrolled in a program to identify if VZV is present and if it is present to identify if it is associated with the wild-type (WT) VZV strain or with the Merck vaccine VZV strain.  The sample of lesion was collected and sent it to the laboratory on 19-MAR-2009.  The sample was taken from a scab.  The PCR results for the specimen from the scab, identified the presence of Wild Type Strain VZV.  Follow up information received on 06-APR-2009 from the physician stated that it was a retired patient with arthritis and no illness at time of vaccination, who on 24-FEB-2009 was vaccinated with a first dose of ZOSTAVAX, (lot # 663895/0135Y), intramuscularly.  On 26-FEB-2009 the patient developed shingles in the right T11.  The patient had a skin scraping.  The patient recovered in April 2009.  No further information is available.
Swelling, redness, hot to touch in a large area covering right upper arm. Prescribed Duricef for 10 days.
Patient's left arm is sore and hurts when she tries to lift left arm. It's been going on for 6 days.
I received 2 doses of the pfizer covid vaccine with my last being 1/8./i still got covid; I received 2 doses of the pfizer covid vaccine with my last being 1/8./i still got covid; This is a spontaneous report from a contactable nurse (patient) via the medical information team. A female patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), first and second dose; both via an unspecified route of administration on an unspecified date (batch/lot number was not reported) as single dose for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient received 2 doses of the pfizer covid vaccine with her last being 8Jan (unspecified date). The patient never take off her N95. The patient was the safest nurse she knew of. The patient didn't go anywhere but work and the store and she still got covid. The patient just wanted to know. The patient couldn't make sense of this. The patient was just diagnosed yesterday (22Feb2021) as tested positive with COVID-19. The outcome of the events was unknown.  Information on the lot/batch number has been requested.; Sender's Comments: Based on the information currently available, a lack of efficacy with bnt162b2 vaccine in this patient cannot be completely excluded.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  An adult male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 07Sep2022 as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Hypertension" (unspecified if ongoing). Concomitant medication(s) included: LOSARTAN. Past drug history included: Bactrin, reaction(s): "Known allergies: Bactrin". The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "recovering" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: COVID 19 Treatment. Therapeutic measures were taken as a result of drug ineffective, covid-19.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
25 doses of expired Moderna Covid-19 vaccine were administered to patients.; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (25 doses of expired Moderna Covid-19 vaccine were administered to patients.) in a 67-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016J21-2A) for COVID-19 vaccination.     No Medical History information was reported.    On 04-May-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 04-May-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (25 doses of expired Moderna Covid-19 vaccine were administered to patients.). At the time of the report, EXPIRED PRODUCT ADMINISTERED (25 doses of expired Moderna Covid-19 vaccine were administered to patients.) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication was not provided.  Patient received Moderna Covid-19 vaccine as booster dose The vaccine was expired on 17-Apr-2022 .The vial was initially stored in the refrigerator on 29-Apr-2022 and 04-May-2022.  Treatment information was not provided.
Sore arm; This spontaneous case was reported by a non-health professional and describes the occurrence of MYALGIA (Sore arm) in a 73-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 046A21A) for COVID-19 vaccination.     The patient's past medical history included Stroke (lead to left arm weakness) in 2019.    On 25-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Mar-2021, the patient experienced MYALGIA (Sore arm). At the time of the report, MYALGIA (Sore arm) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       no concomitant medication and treatment given
Information has been received from a licensed practical nurse referring to a patient of unknown age and gender. The patient's medical history and concurrent condition were not reported. On 16-JUN-2016 the patient received a dose of improperly stored M-M-R II (Lot # L032044, expiration date 24-AUG-2017, dose unknown) intramuscularly (Drug use via unapproved administration route). Concomitant therapy was not reported. The M-M-R II was improperly stored under 49.3 Fahrenheit degree for 20 hours on 06-MAY-2016, 48.88 Fahrenheit degree for 22 minutes on 12-MAY-2016 and 47.04 Fahrenheit degree for 37 minutes on 02-JUN-2016. Cumulatively, the vaccine was stored in maximum temperature 49.3 Fahrenheit degree for 20 hours 59 minutes. Date logger was involved. No adverse effects were reported. Additional information has been requested.
I had muscle spasms in my right arm after receiving the vaccine. I tested positive for COVID-19 in May 2022. In August 2022, I developed Shingles and I have had multiple outbreaks since receiving the vaccine. Also, I developed bronchitis.
Severe headache. Jaw pain. Neck pain muscles in head pain all right right vision.
Swollen Lymph Node in left armpit/general left armpit swelling with pain  (approx. circumference of a baseball). Began 4-5 days post first vaccination dose and has grown in size and worsened in pain. Makes movement of arm uncomfortable and occasionally painful.  At the time of writing this report, it has been 1 week since the first dose and the adverse event persists without signs of alleviation.
Case number PHEH2013US021459 is an initial spontaneous report from the medical assistant received on 11 OCT 2013. This report refers to a patient of an unknown age and gender. The patient accidentally received 0.5 ml intramuscular dose of Men A lyophilized component of MENVEO (batch number: X12100) after reconstitution in a sterile diluent instead of Men CYW-135 liquid component. No adverse event reported following this medication error.